Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Quentin30 is a pathological prevaricator.

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Apr 12, 2024 11:03am

86 Views

Post# 35985676

RE:Quentin30 is a pathological prevaricator.

This thread was created in June 2023 because Quentin30 had repeatedly thrown "shade" over the stock that he said he owned - and he did so by "creating" misinformation, which was challenged with real information on every occassion., thus initiating to the original subject header.

<< Previous

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant